762272-95-7

Upstream product

• 74-88-4 methyl iodide 
• 58824-55-8 1-(3-bromo-phenyl)-prop-2-en-1-ol 
• 3132-99-8 m-bromobenzoic aldehyde 
• 165896-48-0 2-[3-(3-bromo-phenyl)-3-oxo-propyl]-benzoic acid methyl ester 

Downstream Products

• 762272-99-1 (+/-)-1-(3-bromophenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)-1-propanol 
• 165896-48-0 2-[3-(3-bromo-phenyl)-3-oxo-propyl]-benzoic acid methyl ester 
• 1258428-71-5 trans-1-{3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one 
• 762273-01-8 (S)-1-(3-bromo-phenyl)-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propan-1-ol 
• 762272-97-9 1-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one 
• 287930-77-2 (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol 
• 181139-72-0 methyl-[(E)]-2-[3(S)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl] benzoate 

Relevant academic research and scientific papers

Ketone Reductase Biocatalysis in the Synthesis of Chiral Intermediates Toward Generic Active Pharmaceutical Ingredients

A range of generic active pharmaceutical ingredients were examined for potential chiral alcohol motifs and derivatives within their structures that could be employed as key synthetic intermediates. For seven generic active pharmaceutical ingredients (APIs), eight precursor ketones were acquired and then subjected to reduction by >400 commercially available ketone reductases from different suppliers. Positive screening results were achieved for five ketones screened, with multiple ketone reductases available for each successful ketone. Selectivity was typically >99.5% ee in most cases, including for the opposite enantiomer. The three best examples were then optimized and quickly scaled up to 1 L scale in high conversion and isolated yield while retaining selectivity of >99.5% ee for the desired chiral alcohol enantiomer. This work illustrates that where a wide range of enzymes are available, productive enzymes to give either alcohol enantiomer can be readily identified for many ketones and rapidly scaled up to produce chiral alcohols. This approach is particularly applicable to generating chiral API intermediates.

For the synthesis of montelukast intermediate compound and its preparation method

The invention relates to a pharmaceutical intermediate and a preparation method thereof, and especially relates to an intermediate compound represented by the formula (1) for synthesizing montelukast; wherein in the formula the X' represents a halogen ele

The resolution of important pharmaceutical building blocks by palladium-catalyzed aerobic oxidation of secondary alcohols

The palladium-catalyzed aerobic oxidative kinetic resolution of key pharmaceutical building blocks is described. Substrates investigated are relevant to the enantioselective preparation of Prozac, Singulair, and the promising hNK-1 receptor antagonist from Merck. The latter provides the most selective aerobic oxidative kinetic resolution yet described.